Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

cheplapharm arzneimittel gmbh - quetiapine - film-coated tablet - diazepines, oxazepines, thiazepines and oxepines; quetiapine

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

cheplapharm arzneimittel gmbh - quetiapine - film-coated tablet - diazepines, oxazepines, thiazepines and oxepines; quetiapine

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

cheplapharm arzneimittel gmbh - quetiapine - prolonged-release tablet - diazepines, oxazepines, thiazepines and oxepines; quetiapine

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

cheplapharm arzneimittel gmbh - quetiapine - prolonged-release tablet - diazepines, oxazepines, thiazepines and oxepines; quetiapine

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

cheplapharm arzneimittel gmbh - quetiapine - prolonged-release tablet - diazepines, oxazepines, thiazepines and oxepines; quetiapine

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

cheplapharm arzneimittel gmbh - quetiapine - prolonged-release tablet - diazepines, oxazepines, thiazepines and oxepines; quetiapine

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

cheplapharm arzneimittel gmbh - quetiapine - prolonged-release tablet - diazepines, oxazepines, thiazepines and oxepines; quetiapine

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapy:in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - verteporfin - myopia, degenerative; macular degeneration - ophthalmologicals - visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (amd) with predominantly classic subfoveal choroidal neovascularisation (cnv) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia.

Καναδάς - Αγγλικά - Health Canada

cheplapharm arzneimittel gmbh - amphotericin b - powder for solution - 50mg - amphotericin b 50mg - polyenes